Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 31550019.
- Also identified by DOI 10.1001/jama.2019.10650 and PMC identifier 6763996.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This research letter discusses the association between label restrictions by the US Food and Drug Administration on first-line immunotherapy for advanced bladder cancer and subsequent changes in practice.
Medical subject headings
- Antineoplastic Agents
- Drug Labeling
- Drug Therapy
- Immunotherapy
- Programmed Cell Death 1 Receptor
- Urinary Bladder Neoplasms